Real-time enrollment status for this her2 expressing solid tumors clinical trial
Current Status
Recruiting
Checked: August 28, 2026 at 2:52 AM UTC
| NCT Number | NCT07192432 |
| Recruiting Status | Recruiting |
| Condition | HER2 Expressing Solid Tumors |
| Phase | PHASE1 |
| Target Enrollment | 27 participants |
| Active Locations | 11 sites in the US |
| Sponsor | Vironexis Biotherapeutics Inc. |
| Last Updated on CT.gov | July 28, 2026 (Jul 28, 2026) |
As of August 28, 2026: Clinical trial NCT07192432 is currently recruiting participants. This phase1 study for her2 expressing solid tumors is actively seeking new participants at 11 locations across the United States. The study is sponsored by Vironexis Biotherapeutics Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07192432 is actively recruiting participants as of August 28, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 11 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07192432 was last updated Jul 28, 2026 (July 28, 2026). HelloStudys verifies this status automatically.